Moberg Pharma AB (publ)
STO:MOB

Watchlist Manager
Moberg Pharma AB (publ) Logo
Moberg Pharma AB (publ)
STO:MOB
Watchlist
Price: 9.34 SEK -0.64% Market Closed
Market Cap: kr455m

Operating Margin

-2 624.6%
Current
Improving
by 1 682.5%
vs 3-y average of -4 307.1%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-2 624.6%
=
Operating Income
kr-328m
/
Revenue
kr12.5m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-2 624.6%
=
Operating Income
kr-328m
/
Revenue
kr12.5m

Peer Comparison

Country Company Market Cap Operating
Margin
SE
Moberg Pharma AB (publ)
STO:MOB
441.8m SEK
Loading...
US
Eli Lilly and Co
NYSE:LLY
1T USD
Loading...
UK
Dechra Pharmaceuticals PLC
F:1PK
5.1B EUR
Loading...
US
Johnson & Johnson
NYSE:JNJ
529.7B USD
Loading...
CH
Roche Holding AG
SIX:ROG
275.3B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
210.3B GBP
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK
Loading...
CH
Novartis AG
SIX:NOVN
221.9B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
269.1B USD
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
145.8B USD
Loading...

Market Distribution

Lower than 95% of companies in Sweden
Percentile
5th
Based on 2 047 companies
5th percentile
-2 624.6%
Low
-2 025 693.8% — -1.8%
Typical Range
-1.8% — 12.5%
High
12.5% — 10 459.2%
Distribution Statistics
Sweden
Min -2 025 693.8%
30th Percentile -1.8%
Median 6%
70th Percentile 12.5%
Max 10 459.2%

Moberg Pharma AB (publ)
Glance View

Market Cap
455m SEK
Industry
Pharmaceuticals

Moberg Pharma AB is a pharmaceutical company, which engages in the development and commercialization of medical products. The company is headquartered in Bromma, Stockholm. The company went IPO on 2011-05-26. Its product portfolio includes products for the treatment of skin diseases and pain, such as Emtrix/Nalox, for the treatment of nails damaged by fungus or psoriasis; Kerasal, for dry and damaged feet, and Kaprolac, a range of products for several types of skin and scalp problems. Additionally, the Company has two projects in phase II of development, namely MOB-15, for the treatment of nail fungus, and Limtop, for the treatment of actinic keratosis, basalioma and genital warts. The firm collaborates with Meda AB, Menarini Group, Perrigo Company, OzHealth Pharma and Zelmic AB, among others. The company is active in more than 35 countries, and operates, among others, through Alterna LLC. The company also owns three Over-The-Counter (OTC) brands in the United States.

MOB Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-2 624.6%
=
Operating Income
kr-328m
/
Revenue
kr12.5m
What is Moberg Pharma AB (publ)'s current Operating Margin?

The current Operating Margin for Moberg Pharma AB (publ) is -2 624.6%, which is above its 3-year median of -4 307.1%.

How has Operating Margin changed over time?

Over the last 3 years, Moberg Pharma AB (publ)’s Operating Margin has increased from -9 911.6% to -2 624.6%. During this period, it reached a low of -10 545.9% on Jun 30, 2023 and a high of -253.7% on Dec 31, 2024.

Back to Top